Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Amortization of Deferred Charges: 2013-2024

Historic Amortization of Deferred Charges for Zevra Therapeutics (ZVRA) over the last 10 years, with Dec 2024 value amounting to $2.1 million.

  • Zevra Therapeutics' Amortization of Deferred Charges fell 12.07% to $685,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year increase of 60.89%. This contributed to the annual value of $2.1 million for FY2024, which is N/A change from last year.
  • As of FY2024, Zevra Therapeutics' Amortization of Deferred Charges stood at $2.1 million, which was up 1,292.67% from $150,000 recorded in FY2021.
  • Over the past 5 years, Zevra Therapeutics' Amortization of Deferred Charges peaked at $4.7 million during FY2020, and registered a low of $150,000 during FY2021.
  • For the 1-year period, Zevra Therapeutics' Amortization of Deferred Charges averaged around $2.1 million, with its median value being $2.1 million (2024).
  • In the last 5 years, Zevra Therapeutics' Amortization of Deferred Charges surged by 186.29% in 2020 and then tumbled by 96.84% in 2021.
  • Yearly analysis of 3 years shows Zevra Therapeutics' Amortization of Deferred Charges stood at $4.7 million in 2020, then plummeted by 96.84% to $150,000 in 2021, then reached $2.1 million in 2024.